Brain Anatomical Abnormalities in High-Risk Individuals, First-Episode, and Chronic Schizophrenia: An Activation Likelihood Estimation Meta-analysis of Illness Progression

Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China.
Schizophrenia Bulletin (Impact Factor: 8.61). 08/2009; 37(1):177-88. DOI: 10.1093/schbul/sbp073
Source: PubMed

ABSTRACT The present study reviewed voxel-based morphometry (VBM) studies on high-risk individuals with schizophrenia, patients experiencing their first-episode schizophrenia (FES), and those with chronic schizophrenia. We predicted that gray matter abnormalities would show progressive changes, with most extensive abnormalities in the chronic group relative to FES and least in the high-risk group.
Forty-one VBM studies were reviewed. Eight high-risk studies, 14 FES studies, and 19 chronic studies were analyzed using anatomical likelihood estimation meta-analysis.
Less gray matter in the high-risk group relative to controls was observed in anterior cingulate regions, left amygdala, and right insula. Lower gray matter volumes in FES compared with controls were also found in the anterior cingulate and right insula but not the amygdala. Lower gray matter volumes in the chronic group were most extensive, incorporating similar regions to those found in FES and high-risk groups but extending to superior temporal gyri, thalamus, posterior cingulate, and parahippocampal gryus. Subtraction analysis revealed less frontotemporal, striatal, and cerebellar gray matter in FES than the high-risk group; the high-risk group had less gray matter in left subcallosal gyrus, left amygdala, and left inferior frontal gyrus compared with FES. Subtraction analysis confirmed lower gray matter volumes through ventral-dorsal anterior cingulate, right insula, left amygdala and thalamus in chronic schizophrenia relative to FES.
Frontotemporal brain structural abnormalities are evident in nonpsychotic individuals at high risk of developing schizophrenia. The present meta-analysis indicates that these gray matter abnormalities become more extensive through first-episode and chronic illness. Thus, schizophrenia appears to be a progressive cortico-striato-thalamic loop disorder.

  • Source
    • "Schizophrenia is a complex and heterogeneous disorder of neurodevelopment and neuroprogression, including cell dysfunction , apoptotic processes, decreased neurogenesis and neuroplasticity (Davis et al., 2014; Meyer, 2013; Smith and Maes, 1995). The neuroprogression theory of schizophrenia postulates that changes in the immune system are accompanied by increased inflammatory markers, tryptophan catabolites (TRYCATs) and reactive oxygen species (ROS) affecting the growth and function of neuronal circuits since the intra-utero period (Chan et al., 2011). These changes progress over time and coincide with symptomatic deterioration and decreased treatment efficacy (Davis et al., 2014; Pedrini et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is accompanied by increased lipid peroxidation and nitric oxide (NO) levels and by lowered antioxidant levels. However, the effect of antipsychotic agents on these processes remains unclear. The objective of this study is to determine the oxidative stress (OS) status in drug naïve first-episode psychotic patients (FEP) compared to healthy controls and to delineate the effects of risperidone on these biomarkers. 51 drug naive FEP patients and 61 healthy controls were enrolled; FEP patients were reassessed 11 weeks after risperidone treatment. Three OS biomarkers, i.e. lipid hydroperoxides - LOOH, NO metabolites - NOx, and advanced oxidation protein products - AOPP, and two antioxidant biomarkers, i.e. total radical-trapping antioxidant parameter - TRAP, and paraoxonase 1 - PON1, were measured. The Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS) were used to measure symptoms severity. Significantly lower PON1 activity and increased TRAP values were found in FEP patients. There were no significant associations between any of the OS/antioxidant biomarkers and clinical data. Risperidone treatment significantly increased PON1 activity and decreased LOOH levels. These effects of risperidone were not significantly associated with the clinical response and risperidone dosage. Changes in antioxidant profile, but not in lipid or protein oxidation or increased NO production, were found in drug-naive FEP. Risperidone may have antioxidant effects by lowering lipid peroxidation and increasing the antioxidant defenses against lipid peroxidation related to PON1. None of the biomarkers predicted treatment outcome. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Journal of Psychiatric Research 09/2015; 68:210-216. DOI:10.1016/j.jpsychires.2015.07.003 · 4.09 Impact Factor
  • Source
    • "This includes differences in the left inferior frontal/ insular cortex, right thalamus, left hippocampus, and right striatum (see Fig. 3b), where UHR-attenuated symptoms and schizophrenia patients diverge markedly. While the left prefrontal/insular cortex changes were also significant for the comparison of healthy controls with schizophrenia, it is noteworthy that the above regions are among the best-replicated following psychosis onset (Chan et al., 2011). It is, Fig. 1 "
    [Show abstract] [Hide abstract]
    ABSTRACT: While schizophrenia and bipolar disorder have been assumed to share phenotypic and genotypic features, there is also evidence for overlapping brain structural correlates, although it is unclear whether these relate to shared psychotic features. In this study, we used voxel-based morphometry (VBM8) in 34 schizophrenia patients, 17 euthymic bipolar I disorder patients (with a history of psychotic symptoms), and 34 healthy controls. Our results indicate that compared to healthy controls schizophrenia patients show grey matter deficits (p<0.05, FDR corrected) in medial and right dorsolateral prefrontal, as well as bilaterally in ventrolateral prefrontal and insular cortical areas, thalamus (bilaterally), left superior temporal cortex, and minor medial parietal and parietooccipital areas. Comparing schizophrenia vs. bipolar I patients (p<0.05, FDR corrected) yielded a similar pattern, however, there was an additional significant reduction in schizophrenia patients in the (posterior) hippocampus bilaterally, left dorsolateral prefrontal cortex, and left cerebellum. Compared to healthy controls, the deficits in bipolar I patients only reached significance at p<0.001 (uncorr.) for a minor parietal cluster, but not for prefrontal areas. Our results suggest that the more extensive prefrontal, thalamic, and hippocampal deficits that might set apart schizophrenia and bipolar disorder might not be related to mere appearance of psychotic symptoms at some stage of the disorders. Copyright © 2015 Elsevier B.V. All rights reserved.
    Schizophrenia Research 04/2015; 165(2-3). DOI:10.1016/j.schres.2015.04.007 · 4.43 Impact Factor
  • Source
    • "After more than a century of research into the neurobiology of the disorder, its pathophysiological underpinnings still remain unknown. Over the past 15 years, considerable research efforts elucidated a vast array of functional (Howes et al, 2012; Minzenberg et al, 2009) and structural brain abnormalities (Chan et al, 2009; Fornito et al, 2009; Honea et al, 2005) that may constitute the 'organic surrogate' of the illness. Even though these results indicate significant differences in, eg, brain structure between healthy controls (HC) and patients at the group level—a substantial overlap is usually observed between groups, which disallow the use of these differences for the individualized diagnosis of the disorder. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multivariate pattern recognition approaches have recently facilitated the search for reliable neuroimaging-based biomarkers in psychiatric disorders such as schizophrenia. By taking into account the multivariate nature of brain functional and structural changes as well as their distributed localization across the whole brain, they overcome drawbacks of traditional univariate approaches. However reported studies in schizophrenic patients vary widely in terms of their methodology and the clinical samples investigated, leading to heterogeneous results. In order to evaluate the overall reliability of neuroimaging-based biomarkers, we conducted a comprehensive literature search to identify all studies that used multivariate pattern recognition to identify patterns of brain alterations that differentiate patients with schizophrenia from healthy controls. A bivariate random-effects meta-analytic model was implemented to investigate sensitivity and specificity across studies as well as to assess the robustness to potentially confounding variables. In the total sample of n=38 studies (1602 patients and 1637 healthy controls) patients were differentiated from controls with a sensitivity of 80.3% (95%-CI: 76.7 to 83.5%) and a specificity of 80.3% (95%-CI: 76.9 to 83.3%). Moderator analysis identified significant effects of age (p=0.029), imaging modality (p=0.019) and disease stage (p=0.025) on sensitivity as well as of positive-to-negative symptom ratio (p=0.022) and antipsychotic medication (p=0.016) on specificity. Our results underline the utility of multivariate pattern recognition approaches for the identification of reliable neuroimaging-based biomarkers. Despite the clinical heterogeneity of the schizophrenia phenotype, brain functional and structural alterations differentiate schizophrenic patients from healthy controls with 80% accuracy.
    Neuropsychopharmacology 02/2015; 40(7). DOI:10.1038/npp.2015.22 · 7.83 Impact Factor
Show more